Santa Monica, CANCT07671534Now EnrollingIRB Ready

Solid Tumor Cancer Clinical Trial in Santa Monica, CA

Access cutting-edge solid tumor cancer treatment through this clinical trial at a research site in Santa Monica. Study-provided care at no cost to qualified participants.

Sponsored by Sarcoma Oncology Research Center, LLC

Quick Self-Assessment

See if you qualify for this Santa Monica location

Preparing your pre-screening questions…

Expert Care in Santa Monica

Access solid tumor cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumor cancer treatment provided free

Apply for This Santa Monica Location

Check if you qualify for this solid tumor cancer clinical trial in Santa Monica, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Santa Monica

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Santa Monica site if eligible
  4. 4Begin participation

About This Solid Tumor Cancer Study in Santa Monica

This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.

Sponsor: Sarcoma Oncology Research Center, LLC

Who Can Participate

Inclusion Criteria

Male or Female ≥ 18 years of age
Pathologically confirmed diagnosis of locally advanced or metastatic solid tumor
Previously treated participants
Measurable disease by RECIST v1.1
ECOG performance status ≤ 1
Life expectancy of at least 3 months
Acceptable liver function: Bilirubin ≤ 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level \< 3.0 ULN); AST (SGOT), ALT (SGPT) and alkaline phosphatase ≤ 3 x ULN (\< 5 x ULN if liver metastases); Acceptable renal function: Creatinine \< 1.5 times ULN
Acceptable hematologic status (without hematologic support e.g. growth factors or transfusion within 21 days of first dose of study agents): ANC ≥ 1500 cells/μL; Platelet count ≥ 100,000/μL; Hemoglobin ≥ 9.0 g/dL; Normal PT, PTT, INR
All women of childbearing potential must have a negative pregnancy test and all subjects must agree to use highly effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 5 months for women and 7 months for men after the last dose.
Females of reproductive potential must have 2 negative pregnancy tests before initiating THALOMID. The first test should be performed within 10-14 days, and the second test within 24 hours prior to prescribing THALOMID. Once treatment has started and during dose interruptions, pregnancy testing for females of reproductive potential should occur weekly during the first 4 weeks of use, then pregnancy testing should be repeated every 4 weeks in females with regular menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in her menstrual bleeding. THALOMIDE treatment must be discontinued during this evaluation.
Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the principal investigator's IRB/Ethics Committee
Willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria

Subjects with untreated CNS metastases. Subjects are eligible if CNS metastases have been adequately treated and have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to treatment initiation. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of \<10 mg daily prednisone (or equivalent) for at least 2 weeks prior to treatment initiation.
Subjects with carcinomatous meningitis
Subjects who participated in an investigational drug or device study within 14 days prior to study entry
Subjects who had chemotherapy within 14 days prior to study entry
Females who are pregnant or breast-feeding
Unwillingness or inability to comply with the study protocol for any reason
Evidence of severe or uncontrolled systemic disease or any other concurrent condition, including psychiatric, which in the principal investigator's opinion makes it undesirable for the participant to participate in the trial or which would jeopardize compliance with the trial
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Santa Monica?

Yes, this clinical trial (NCT07671534) has an active research site in Santa Monica, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumor Cancer Treatment Options in Santa Monica, CA

If you're searching for solid tumor cancer treatment options in Santa Monica, CA, this clinical trial (NCT07671534) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Santa Monica research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumor cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumor cancer clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Santa Monica, CA

See all advanced solid tumors clinical trials recruiting in Santa Monica — not just this study.

Browse Advanced Solid Tumors Trials in Santa Monica →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Santa Monica?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Santa Monica, CA